- Home
- GILD vs ADBE Comparison
GILD vs ADBE Comparison
Compare GILD & ADBE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GILD
- ADBE
- Stock Information
- Founded
- GILD 1987
- ADBE 1982
- Country
- GILD United States
- ADBE United States
- Employees
- GILD N/A
- ADBE N/A
- Industry
- GILD Biotechnology: Biological Products (No Diagnostic Substances)
- ADBE Computer Software: Prepackaged Software
- Sector
- GILD Health Care
- ADBE Technology
- Exchange
- GILD Nasdaq
- ADBE Nasdaq
- Market Cap
- GILD 144.1B
- ADBE 141.5B
- IPO Year
- GILD 1992
- ADBE 1986
- Fundamental
- Price
- GILD $115.05
- ADBE $348.97
- Analyst Decision
- GILD Buy
- ADBE Buy
- Analyst Count
- GILD 23
- ADBE 22
- Target Price
- GILD $115.68
- ADBE $483.35
- AVG Volume (30 Days)
- GILD 5.9M
- ADBE 3.5M
- Earning Date
- GILD 11-05-2025
- ADBE 09-11-2025
- Dividend Yield
- GILD 2.75%
- ADBE N/A
- EPS Growth
- GILD 496.80
- ADBE 40.56
- EPS
- GILD 5.01
- ADBE 15.63
- Revenue
- GILD $28,863,000,000.00
- ADBE $22,601,000,000.00
- Revenue This Year
- GILD $2.01
- ADBE $11.79
- Revenue Next Year
- GILD $4.03
- ADBE $9.41
- P/E Ratio
- GILD $22.96
- ADBE $22.33
- Revenue Growth
- GILD 3.81
- ADBE 10.63
- 52 Week Low
- GILD $77.74
- ADBE $330.04
- 52 Week High
- GILD $121.83
- ADBE $587.75
- Technical
- Relative Strength Index (RSI)
- GILD 52.20
- ADBE 45.43
- Support Level
- GILD $111.28
- ADBE $331.50
- Resistance Level
- GILD $118.13
- ADBE $364.65
- Average True Range (ATR)
- GILD 2.06
- ADBE 7.70
- MACD
- GILD -0.46
- ADBE -0.05
- Stochastic Oscillator
- GILD 39.23
- ADBE 52.70
About GILD Gilead Sciences Inc.
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
About ADBE Adobe Inc.
Adobe provides content creation, document management, and digital marketing and advertising software and services to creative professionals and marketers for creating, managing, delivering, measuring, optimizing, and engaging with compelling content multiple operating systems, devices, and media. The company operates with three segments: digital media content creation, digital experience for marketing solutions, and publishing for legacy products (less than 5% of revenue).